BD Reports Strong Fourth Quarter and Fiscal 2026 Results as Earnings Rise

what happened

US medical technology company BD (Becton, Dickinson and Company) published results for its fourth quarter and full fiscal 2026, which ended September 30. Quarterly revenue reached $5.3 billion, up 5.4% as reported and 5.6% on a foreign-currency-neutral basis. Adjusted diluted earnings per share came in at $4.15, compared with $3.26 a year earlier.

For the full year, revenue totaled $19.5 billion, growing 4.9%, while free cash flow rose 42.5% to $2.9 billion. BD also announced a partnership with the US government to expand domestic manufacturing. The company intends to invest $19 billion in the US over several years, with $3 billion aimed at manufacturing expansion. The deal provides relief from future Section 232 tariffs on covered products, subject to agreed milestones.

For fiscal 2027, BD guided to adjusted diluted EPS of $13.10 to $13.30 and low single-digit revenue growth.

why it matters

The combination of faster profit growth and a firm outlook matters for medtech, a sector sensitive to demand stability and costs. The spin-off of the Biosciences and Diagnostic Solutions business, completed on February 9, 2026, has left BD more focused on medical products. Investors will next look to the company's 2026 Investor Day on December 10 at the New York Stock Exchange.

market impact

BD shares and medtech sector: strong results and US investment plan support interest in the stock

• ▲BD shares pressure up — revenue and adjusted EPS grew faster than a year earlier

tags

instruments